Cargando…

Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia

AIM: To study the effect of itopride on gastric accommodation, gastric emptying and drinking capacity in functional dyspepsia (FD). METHODS: Randomized controlled trial was conducted to check the effect of itopride on gastric accommodation, gastric emptying, capacity of tolerating nutrient liquid an...

Descripción completa

Detalles Bibliográficos
Autores principales: Abid, Shahab, Jafri, Wasim, Zaman, Maseeh Uz, Bilal, Rakhshanda, Awan, Safia, Abbas, Aamir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292610/
https://www.ncbi.nlm.nih.gov/pubmed/28217377
http://dx.doi.org/10.4292/wjgpt.v8.i1.74
_version_ 1782504955428470784
author Abid, Shahab
Jafri, Wasim
Zaman, Maseeh Uz
Bilal, Rakhshanda
Awan, Safia
Abbas, Aamir
author_facet Abid, Shahab
Jafri, Wasim
Zaman, Maseeh Uz
Bilal, Rakhshanda
Awan, Safia
Abbas, Aamir
author_sort Abid, Shahab
collection PubMed
description AIM: To study the effect of itopride on gastric accommodation, gastric emptying and drinking capacity in functional dyspepsia (FD). METHODS: Randomized controlled trial was conducted to check the effect of itopride on gastric accommodation, gastric emptying, capacity of tolerating nutrient liquid and symptoms of FD. We recruited a total of 31 patients having FD on the basis of ROME III criteria. After randomization, itopride was received by 15 patients while 16 patients received placebo. Gastric accommodation was determined using Gastric Scintigraphy. (13)C labeled octanoic breadth test was performed to assess gastric emptying. Capacity of tolerating nutrient liquid drink was checked using satiety drinking capacity test. The intervention group comprised of 150 mg itopride. Patients in both arms were followed for 4 wk. RESULTS: Mean age of the recruited participant 33 years (SD = 7.6) and most of the recruited individuals, i.e., 21 (67.7%) were males. We found that there was no effect of itopride on gastric accommodation as measured at different in volumes in the itopride and control group with the empty stomach (P = 0.14), at 20 min (P = 0.38), 30 min (P = 0.30), 40 min (P = 0.43), 50 min (P = 0.50), 60 min (P = 0.81), 90 min (P = 0.25) and 120 min (P = 0.67). Gastric emptying done on a sub sample (n = 11) showed no significant difference (P = 0.58) between itopride and placebo group. There was no significant improvement in the capacity to tolerate liquid in the itopride group as compared to placebo (P = 0.51). Similarly there was no significant improvement of symptoms as assessed through a composite symptom score (P = 0.74). The change in QT interval in itopride group was not significantly different from placebo (0.10). CONCLUSION: Our study found no effect of itopride on gastric accommodation, gastric emptying and maximum tolerated volume in patients with FD.
format Online
Article
Text
id pubmed-5292610
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-52926102017-02-17 Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia Abid, Shahab Jafri, Wasim Zaman, Maseeh Uz Bilal, Rakhshanda Awan, Safia Abbas, Aamir World J Gastrointest Pharmacol Ther Randomized Controlled Trial AIM: To study the effect of itopride on gastric accommodation, gastric emptying and drinking capacity in functional dyspepsia (FD). METHODS: Randomized controlled trial was conducted to check the effect of itopride on gastric accommodation, gastric emptying, capacity of tolerating nutrient liquid and symptoms of FD. We recruited a total of 31 patients having FD on the basis of ROME III criteria. After randomization, itopride was received by 15 patients while 16 patients received placebo. Gastric accommodation was determined using Gastric Scintigraphy. (13)C labeled octanoic breadth test was performed to assess gastric emptying. Capacity of tolerating nutrient liquid drink was checked using satiety drinking capacity test. The intervention group comprised of 150 mg itopride. Patients in both arms were followed for 4 wk. RESULTS: Mean age of the recruited participant 33 years (SD = 7.6) and most of the recruited individuals, i.e., 21 (67.7%) were males. We found that there was no effect of itopride on gastric accommodation as measured at different in volumes in the itopride and control group with the empty stomach (P = 0.14), at 20 min (P = 0.38), 30 min (P = 0.30), 40 min (P = 0.43), 50 min (P = 0.50), 60 min (P = 0.81), 90 min (P = 0.25) and 120 min (P = 0.67). Gastric emptying done on a sub sample (n = 11) showed no significant difference (P = 0.58) between itopride and placebo group. There was no significant improvement in the capacity to tolerate liquid in the itopride group as compared to placebo (P = 0.51). Similarly there was no significant improvement of symptoms as assessed through a composite symptom score (P = 0.74). The change in QT interval in itopride group was not significantly different from placebo (0.10). CONCLUSION: Our study found no effect of itopride on gastric accommodation, gastric emptying and maximum tolerated volume in patients with FD. Baishideng Publishing Group Inc 2017-02-06 2017-02-06 /pmc/articles/PMC5292610/ /pubmed/28217377 http://dx.doi.org/10.4292/wjgpt.v8.i1.74 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Randomized Controlled Trial
Abid, Shahab
Jafri, Wasim
Zaman, Maseeh Uz
Bilal, Rakhshanda
Awan, Safia
Abbas, Aamir
Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
title Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
title_full Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
title_fullStr Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
title_full_unstemmed Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
title_short Itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
title_sort itopride for gastric volume, gastric emptying and drinking capacity in functional dyspepsia
topic Randomized Controlled Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292610/
https://www.ncbi.nlm.nih.gov/pubmed/28217377
http://dx.doi.org/10.4292/wjgpt.v8.i1.74
work_keys_str_mv AT abidshahab itoprideforgastricvolumegastricemptyinganddrinkingcapacityinfunctionaldyspepsia
AT jafriwasim itoprideforgastricvolumegastricemptyinganddrinkingcapacityinfunctionaldyspepsia
AT zamanmaseehuz itoprideforgastricvolumegastricemptyinganddrinkingcapacityinfunctionaldyspepsia
AT bilalrakhshanda itoprideforgastricvolumegastricemptyinganddrinkingcapacityinfunctionaldyspepsia
AT awansafia itoprideforgastricvolumegastricemptyinganddrinkingcapacityinfunctionaldyspepsia
AT abbasaamir itoprideforgastricvolumegastricemptyinganddrinkingcapacityinfunctionaldyspepsia